Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Juglone is a naturally occurring **naphthoquinone derivative** with the chemical formula C10H6O3, mainly found in the black walnut (Juglans nigra) and other plants in the Juglandaceae family[1][2][4][8]. Its primary physiological role in nature is as an **allelopathic agent**—it inhibits the growth of surrounding plants. Juglone has been studied for several bioactivities, notably as an **irreversible inhibitor of peptidyl-prolyl cis/trans isomerases of the parvulin family** (including human Pin1)[2][3]. It also inhibits **RNA polymerases I, II, and III** at low micromolar concentrations[2]. Juglone exerts complex oxidative effects, acting as both a **pro-oxidant and, at some concentrations, an antioxidant**. It also chelates metal ions, such as iron, which can modulate oxidative stress[3]. Juglone is toxic to many organisms and has seen occasional use as an herbicide, anthelmintic, dye (C.I. Natural Brown 7), and, experimentally, as an antibacterial and antifungal agent[1][4][5]. It is not an approved pharmaceutical and is mainly of research interest.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on juglone.